Tag: CorMatrix

CorMatrix® Cardiovascular, Inc. receives FDA approval to expand and enroll 20 additional patients in the adult arm of its early feasibility IDE study of the Cor® TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Feb. 7, 2020 /PRNewswire/ — CorMatrix®Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for its early feasibility IDE study of the Cor® TRICUSPID ECM® valve* for […]

CorMatrix® Cardiovascular, Inc. announces the first minimally invasive robotic implant of Cor® PATCH for epicardial support and repair

ATLANTA, Jan. 28, 2020 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announces the first minimally invasive robotic implant of Cor® PATCH by Dr. Husam H. Balkhy, Professor of Surgery, and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine. Dr. Balkhy is a global leader […]

CorMatrix® Cardiovascular, Inc. completes enrollment of adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Sept. 26, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced it has completed enrollment of the adult arm of its FDA early feasibility IDE study for the Cor® TRICUSPID ECM® cardiac valve* for adults with endocarditis and for pediatric patients with congenital heart valve disease. The Cor® TRICUSPID ECM® valve […]

CorMatrix® Cardiovascular, Inc. receives FDA 510(k) clearance to market the Cor™ PATCH epicardial patch for tissue support and repair in adult patients

ATLANTA, June 11, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA 510(k) clearance for the Cor™ PATCH.  The Cor™ PATCH is indicated for epicardial tissue support and repair in adult patients. The Cor™ PATCH epicardial patch is the first epicardial cardiovascular medical device composed of first next […]

Rebirth of a Heart Valve: Franciscan Health Surgeon First in World to Use Device

INDIANAPOLIS, Feb. 21, 2019 /PRNewswire/ — A patient who received a first-in-the-world tricuspid valve procedure as part of a new national clinical trial at Franciscan Health Heart Center is home and recovering well. The procedure utilizes a revolutionary material called extracellular matrix. The material provides a seamless valve structure which engages and […]

CorMatrix® Cardiovascular, Inc. receives FDA IDE approval to conduct the safety and feasibility clinical trial of the Cor™ TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Jan. 24, 2019 /PRNewswire/ — CorMatrix® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA approval of an early feasibility study IDE to evaluate the safety and feasibility of the Cor™ TRICUSPID ECM® cardiac valve for adults with endocarditis and for pediatric patients with congenital heart valve disease. The […]

Aziyo Continues Building New Breed of Regenerative Medicine Company

SILVER SPRING, Md.–(BUSINESS WIRE)–Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix� Cardiovascular, Inc. for the purchase of all CorMatrix  commercial assets and related intellectual property. With the acquisition, Aziyo will: Add 5 commercially marketed products Double topline revenue Add […]